Evidence and unresolved questions in pulmonary hypertension: Insights from the 5th French Pulmonary Hypertension Network Meeting - 07/07/24

Doi : 10.1016/j.resmer.2024.101123

Athénaïs Boucly ^a,^b,^c, Laurent Bertoletti ^d, Charles Fauvel ^e, Mélanie Gallant Dewavrin ^f, Christian Gerges ^g, Julien Grynblat ^a, Christophe Guignabert ^a,^c, Sébastien Hascoet ^a,^h, Xavier Jaïs ^a,^b,^c, Etienne-Marie Jutant ⁱ, Nicolas Lamblin ^j, Olivier Meyrignac ^k, Marianne Riou ^l, Laurent Savale ^a,^b,^c, Cécile Tromeur ^m, Ségolène Turquier ⁿ, Simon Valentin ^o, Gérald Simonneau ^a,^b,^c, Marc Humbert ^a,^b,^c, Olivier Sitbon ^a,^b,^c, David Montani ^a,^b,^c,^⁎
on behalf on the French PH Network
^a University of Paris-Saclay, School of Medicine, le Kremlin-Bicêtre, France
^b Assistance Publique − Hôpitaux de Paris (AP-HP), Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Bicêtre Hospital, le Kremlin-Bicêtre, France
^c INSERM UMR_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Marie Lannelongue Hospital and Bicêtre Hospital, France
^d Département of Médecine Vasculaire et Thérapeutique, Université Jean Monnet Saint-Étienne, CHU Saint-Étienne, Mines Saint-Étienne, INSERM, SAINBIOSE U1059, CIC 1408, Saint-Étienne, France
^e Normandie Univ, UNIROUEN, U1096, CHU Rouen, Department of Cardiology, F-76000 Rouen, France
^f Association des Malades, Aidants et Transplantés Hypertension Pulmonaire: HTaP France
^g Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria
^h Hôpital Marie Lannelongue, Faculté de Médecine, Paris-Saclay, Université Paris-Saclay, Le Plessis Robinson, France
ⁱ Respiratory Department, CHU de Poitiers, INSERM CIC 1402, IS-ALIVE Research Group, University of Poitiers, Poitiers, France
^j Urgences et Soins Intensifs de Cardiologie, CHU Lille, University of Lille, Inserm U1167, Lille, France
^k Assistance Publique - Hôpitaux de Paris (AP-HP) - Biomaps - Laboratoire d'Imagerie Multimodale - CEA - INSERM - CNRS, DMU 14 Smart Imaging - Department of Radiology, Bicetre Hospital, Le Kremlin-Bicêtre, France
^l Department of Physiology and Functional Exploration, Nouvel Hôpital Civil, University Hospital of Strasbourg, Strasbourg, France
^m Department of Internal Medicine and Pulmonology, CHU Brest, France. INSERM 1304 GETBO (groupe d’étude de thrombose et de bretagne occidentale), Brest, France
ⁿ Department of Physiology and Functional Exploration, Hôpital Louis Pradel, Hospices Civils de Lyon, University of Lyon, Lyon, France
^o Université de Lorraine, CHRU-Nancy, Pôle des Spécialités Médicales/Département de Pneumologie- IADI, INSERM U1254, Nancy, France

^⁎Corresponding author at: Department of Respiratory and Intensive Care Medicine, 78 rue du général Leclerc, 94270 Le Kremlin Bicêtre, France.Department of Respiratory and Intensive Care Medicine78 rue du général LeclercLe Kremlin Bicêtre94270France

Abstract

Pulmonary hypertension (PH) continues to present significant challenges to the medical community, both in terms of diagnosis and treatment. The advent of the updated 2022 European Society of Cardiology (ESC) and European Respiratory Society (ERS) guidelines has introduced pivotal changes that reflect the rapidly advancing understanding of this complex disease. These changes include a revised definition of PH, updates to the classification system, and treatment algorithm. While these guidelines offer a critical framework for the management of PH, they have also sparked new discussions and questions. The 5th French Pulmonary Hypertension Network Meeting (Le Kremlin-Bicêtre, France, 2023), addressed these emergent questions and fostering a deeper understanding of the disease's multifaceted nature. These discussions were not limited to theoretical advancements but extended into the practical realms of patient management, highlighting the challenges and opportunities in applying the latest guidelines to clinical practice.

Le texte complet de cet article est disponible en PDF.

Keywords : Guidelines, Pulmonary hypertension, Definition, Classification, Hemodynamics

Plan

Introduction

Pulmonary hypertension: the patient's perspective

Definition and classification of pulmonary hypertension

Will right heart catheterisation give way to imaging?

Management of pulmonary arterial hypertension

PH associated with lung diseases

Specific situations

Conclusion

✰	With the endorsement of the World Symposium on Pulmonary Hypertension (WSPH) Association, French Language Respiratory Society (Société de Pneumologie de Langue Française, SPLF), and the Rare Diseases Network RespiFil.

Export

Vol 86

Article 101123- novembre 2024 Retour au numéro

Article précédent

Pulmonary nodules and the psychological harm they can cause: A scoping review
Grace C. Hillyer, Nicole Milano, William A. Bulman

| Article suivant

Malignant solitary fibrous tumor of the pleura: A narrative review of clinical characteristics, diagnosis and therapeutic options
Xuehan Gao, Jiaqi Zhang, Zhihong Qian, Lei Liu, Guige Wang, Yang Song, Shanqing Li

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Evidence and unresolved questions in pulmonary hypertension: Insights from the 5th French Pulmonary Hypertension Network Meeting - 07/07/24

Abstract

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL